Genetically determined myocarditis: Clinical presentation and immunological characteristics

Current Opinion in Cardiology

Volumn 23, Issue 3, 2008, Pages 219-226

  Caforio, Alida L P ^a   Iliceto, Sabino ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antibodies; Cardiomyopathy; Immunology; Myocarditis

Indexed keywords

AUTOANTIBODY; BETA ADRENERGIC RECEPTOR; CARDIAC MYOSIN; IMMUNOGLOBULIN G; MUSCARINIC M3 RECEPTOR;

ANTIBODY SPECIFICITY; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MYOCARDITIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; CARDIAC MYOSINS; CARDIOMYOPATHY, DILATED; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOGLOBULIN G; MYOCARDITIS; MYOCARDIUM; ORGAN SPECIFICITY;

EID: 41849127515     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3282fbf572     Document Type: Review

References (93)

1. Karkkainen S, Peuhkurinen K. Genetics of dilated cardiomyopathy. Ann Med 2007; 39:91-107. This is an interesting review concerning the disease-associated mutations in monogenic forms of familial DCM.
2. MacLellan RW, Lusis AJ. Dilated cardiomyopathy: learning to live with yourself. Nat Med 2003; 9:1455-1456.
3. Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003; 9:1477-1483.
4. Eriksson U, Ricci R, Hunziker L, et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 2003; 9:1484-1490.
5. Richardson P, McKenna WJ, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996; 93:841-842.
6. Caforio ALP, McKenna WJ. Recognition and optimum treatment of myocarditis. Drugs 1996; 52:515-525.
7. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of cardiomyopathies. An American Heart Association Scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; quality of Care and Outcome research and Functional Genomics and Translational Biology Interdisciplinary Working Groups: and Council on Epidemiology and Prevention. Circulation 2006; 113:1807-1816.
8. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial disease. Eur Heart J 2008; 29:270-276. doi: 10.1093/eurheartj/ehm342. This is the latest European Society of Cardiology proposal of revision for the 1995 WHO classification of the cardiomyopathies (see Ref. [5]).
9. Pauschinger M, Noutsias M, Lassner D, et al. Inflammation, ECG changes and pericardial effusion. Whom to biopsy in suspected myocarditis? Clin Res Cardiol 2006; 95:569-583.
10. Magnani JW, Dec WG. Myocarditis. Current trends in diagnosis and treatment. Circulation 2006; 113:876-890.
11. Caforio ALP, Calabrese F, Angelini A, et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007; 28:1326-1333. This is a recent prospective study in myocarditis patients admitted at a tertiary referral center. Using current immunohistochemical, immunological, and virological tools to establish etiopathogenetic diagnosis, it was found that the majority of cases were immune-mediated. Viral genome was a univariate predictor of adverse prognosis. Biventricular dysfunction at presentation was the main predictor of adverse outcome.
12. Marin-Neto JA, Cuhna-Neto E, Maciel BC, Simoes MV. Pathogenesis of chronic Chagas heart disease. Circulation 2007; 115:1109-1123. This is an important review summarizing current evidence in relation to pathogenesis of chronic Chagas disease, and in particular the complex interplay of low-grade but incessant systemic infection and immune-mediated adverse reactions.
13. Maekawa Y, Ouzounian M, Opavsky A, Liu PP. Connecting the missing link between dilated cardiomyopathy and viral myocarditis: virus, cytoskeleton and innate immunity. Circulation 2007; 115:5-8. This is an interesting short review dealing with the molecular mechanisms emerging from most recent experimental models on the integration between cardiotropic virus infection in a susceptible host and deleterious immune mechanisms leading from viral myocarditis to DCM.
14. Li Y, Heuser JS, Cunningham LC, et al. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol 2006; 177:8234-8240.
15. Rose NR. Viral damage or 'molecular mimicry' - placing the blame in myocarditis. Nat Med 2000; 6:631-632.
16. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993; 14:426-428.
17. Aretz HT, Billingham ME, Edwards WE, et al. Myocarditis: a histopathologic definition and classification. Am J Cardiol Pathol 1985; 1:1-10.
18. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14000 cases of seven common diseases and shared controls. Nature 2007; 447:661-683. This is an outstanding genome-wide association study on a very large number of patients and controls, reporting new genetic susceptibility loci as well as validating previously reported loci in several complex polygenic human diseases, including autoimmune diseases such as rheumatoid arthritis, T1D, and Crohn's disease.
19. The International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357:1-12. This is a genome-wide association study describing new genetic susceptibility loci and validating previously reported loci in multiple sclerosis, a recognized autoimmune disease. Alleles of the interleukin-7 receptor a gene, of the interleukin-2 receptor α gene and in the HLA-DRA locus were identified as heritable risk factors.
20. Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007; 39:857-864. This is a genome-wide association study on a very large number of patients and controls, reporting four new susceptibility loci in T1D, increasing the number from 6 to at least 10.
21. Lowe CE, Cooper JD, Brusko T, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate a polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007; 39:1074-1082. This is an important study providing evidence for involvement of the IL2RA region, previously associated with autoimmune thyroid disease, in T1D susceptibility. Furthermore, IL2RA susceptibility alleles were correlated with lower circulatory levels of the biomarker soluble IL-2RA, suggesting that an inherited lower immune responsiveness predisposes to T1D.
22. Nejentsev S, Howson JMM, Walker NM, et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007; 450:887-892. doi: 10.1038/nature06406. This is an important study showing for the first time that, in addition to the well known susceptibility role of MHC class II genes, class I genes also are involved in T1D.
23. Lamparter S, Pankuweit S, Maisch B. Clinical and immunological characteristics in peripartum cardiomyopathy. Int J Cardiol 2007; 118:14-20. This is an interesting clinical series of peripartum cardiomyopathies proving evidence for the presence of an underlying autoimmune myocarditis in this rare cardiomyopathy.
24. Portig I, Wilke A, Freyland M, et al. Familial inflammatory dilated cardiomyopathy. Eur J Heart Fail 2006; 8:816-825.
25. Mestroni L, Rocco C, Gregori D, et al. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. J Am Coll Cardiol 1999; 34:181-190.
26. Basso C, Thiene G, Corrado D, et al. Arrhythmogenic right ventricular cardiomyopathy: dysplasia, dystrophy or myocarditis? Circulation 1996; 94:983-991.
27. Frustaci A, Verardo R, Caldarulo M, et al. Myocarditis in hypertrophic cardiomyopathy patients presenting acute clinical deterioration. Eur Heart J 2007; 28:733-740. This is an intriguing yet interesting study describing biopsy-proven viral myocarditis in association with acute clinical deterioration in a monogenic sarcomeric disease, hypertrophic cardiomyopathy. If independently confirmed by others, it could provide an interesting link between observations in animal models and human disease. Genetically diseased myocardium could be more susceptible to viral and/or immune-mediated damage.
28. Frustaci A, Priori SG, Pieroni M, et al. Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. Circulation 2005; 112:3680-3687.
29. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 2007; 50:1914-1931. This is the recently published scientific statement on the role of EMB, reflecting a renewed interest in this technique as a diagnostic and research tool.
30. Skouri HN, Dec W, Friedrich MG, et al. Noninvasive imaging in myocarditis. J Am Coll Cardiol 2006; 48:2085-2093.
31. Mahrholdt H, Wagner A, Deluigi CC, et al. Presentations, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006; 114:1581-1590.
32. Caforio ALP, Stewart JT, Bonifacio E, et al. Inappropriate major histocompatibility complex expression on cardiac tissue in dilated cardiomyopathy. Relevance for autoimmunity? J Autoimmun 1990; 3:187-190.
33. Mahon NG, Madden B, Caforio ALP, et al. Immunohistochemical evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy. J Am Coll Cardiol 2002; 39:455-462.
34. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy. Two-year follow-up results. Circulation 2001; 104:39-45.
35. Mahon NG, Murphy RT, MacRae C, et al. Echocardiographic evaluation in asymptomatic relatives of dilated cardiomyopathy patients reveals preclinical disease. Ann Intern Med 2005; 143:108-115.
36. Caforio ALP, Keeling PJ, Zachara E, et al. Evidence from family studies for autoimmunity in dilated cardiomyopathy. Lancet 1994; 344:773-777.
37. Caforio ALP, Mahon NG, Baig KM, et al. Prospective familial assessment in dilated cardiomyopathy. Cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation 2007; 115:76-83. This is the first prospective family study in DCM relatives showing that cardiac autoantibodies predict disease development at 5 years even in the absence of echocardiographic abnormalities.
38. Anderson JL, Carlquist JF, Lutz JR, et al. HLA A, B, and DR typing in idiopathic dilated cardiomyopathy: a search for immune response factors. Am J Cardiol 1984; 53:1326-1330.
39. Fletcher GF, Wenger NK. Autoimmune studies in patients with primary myocardial disease. Circulation 1968; 37:1032-1035.
40. Camp FT, Hess EV, Conway G, et al. Immunologic findings in idiopathic cardiomyopathy. Am Heart J 1969; 77:610-615.
41. Kirsner AB, Hess EV, Fowler NO. Immunologic findings in idiopathic cardiomyopathy: a prospective serial study. Am Heart J 1973; 86:625-630.
42. Maisch B, Deeg P, Liebau G, et al. Diagnostic relevance of humoral and cytotoxic immune reactions in primary and secondary dilated cardiomyopathy. Am J Cardiol 1983; 52:1071-1078.
43. Maisch B, Deeg P, Liebau G, et al. Diagnostic relevance of humoral and cell-mediated immune reactions in patients with viral myocarditis. Clin Exp Immunol 1983; 48:533-545.
44. Neumann DA, Burek CL, Baughman KL, et al. Circulating heart-reactive antibodies in patients with myocarditis or cardiomyopathy. J Am Coll Cardiol 1990; 16:839-846.
45. Caforio ALP, Bonifacio E, Stewart JT, et al. Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol 1990; 15:1527-1534.
46. Caforio ALP, Wagner R, Gill JS, et al. Organ-specific cardiac antibodies: serological markers for systemic hypertension in autoimmune polyendocrinopathy. Lancet 1991; 337:1111-1115.
47. Caforio ALP, Goldman JH, Haven AJ, et al. Circulating cardiac autoantibodies as markers of autoimmunity in clinical and biopsy-proven myocarditis. Eur Heart J 1997; 18:270-275.
48. Caforio ALP, Grazzini M, Mann JM, et al. Identification of α and β cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 1992; 85:1734-1742.
49. Lauer B, Schannwell M, Kuhl U, et al. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 2000; 35:11-18.
50. Latif N, Baker CS, Dunn MJ, et al. Frequency and specificity of antiheart antibodies in patients with dilated cardiomyopathy detected using SDS-PAGE and western blotting. J Am Coll Cardiol 1993; 22:1378-1384.
51. Goldman JH, Keeling PJ, Warraich RS, et al. Autoimmunity to α-myosin in a subset of patients with idiopathic dilated cardiomyopathy. Br Heart J 1995; 74:598-603.
52. Michels VV, Moll PP, Rodeheffer RJ, et al. Circulating heart autoantibodies in familial as compared with nonfamilial idiopathic dilated cardiomyopathy. Mayo Clin Proc 1994; 69:24-27.
53. Konstandoulakis MM, Kroumbouzou H, Tsiamis E, et al. Clinical significance of antibodies against tropomyosin, actin and myosin in patients with dilated cardiomyopathy. J Clin Lab Immunol 1993; 40:61-67.
54. Warraich RS, Dunn MJ, Yacoub MH. Subclass specificity of autoantibodies against myosin in patients with idiopathic dilated cardiomyopathy: proinflammatory antibodies in dilated cardiomyopathy patients. Biochem Biophys Res Commun 1999; 259:255-261.
55. Portig I, Pankuweit S, Maisch B. Antibodies against stress proteins in sera of patients with dilated cardiomyopathy. J Mol Cell Cardiol 1997; 29:2245-2251.
56. Latif N, Smith J, Dunn MJ, et al. Complement-mediated cytotoxic activity of antiheart antibodies present in the sera of patients with dilated cardiomyopathy. Autoimmunity 1994; 19:99-104.
57. Staudt A, Eichler P, Trimpert C, et al. Fcγ receptors IIa on cardiomyocytes and their potential functional relevance in dilated cardiomyopathy. J Am Coll Cardiol 2007; 49:1684-1692. This is a study showing another potential mechanism for antibody-induced impairment of cardiac function in DCM patients.
58. Baba A, Yoshikawa T, Ogawa S. Autoantibodies against sarcolemmal Na-K-ATPase: possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy. J Am Coll Cardiol 2002; 40:1153-1159.
59. Wolff PG, Kuhl U, Schultheiss HP. Laminin distribution and autoantibodies to laminin in dilated cardiomyopathy and myocarditis. Am Heart J 1989; 117:1303-1309.
60. Klein R, Maisch B, Kochsiek K, et al. Demonstration of organ specific antibodies against heart mitochondria (anti-M7) in sera from patients with some forms of heart diseases. Clin Exp Immunol 1984; 58:283-292.
61. Otto A, Stahle I, Klein R, et al. Antimitochondrial antibodies in patients with dilated cardiomyopathy (anti-M7) are directed against flavoenzymes with covalently bound FAD. Clin Exp Immunol 1998; 111:541-547.
62. Schultheiss HP, Bolte HD. Immunological analysis of auto-antibodies against the adenine nucleotide translocator in dilated cardiomyopathy. J Mol Cell Cardiol 1985; 17:603-617.
63. Schultheiss HP, Kuhl U, Schwimmbeck P, et al. Biomolecular changes in dilated cardiomyopathy. In: Baroldi G, Camerini F, Goodwin JF, editors. Advances in cardiomyopathies. Berlin: Springer Verlag; 1990. pp. 221-234.
64. Ansari AA, Neckelmann N, Villinger F, et al. Epitope mapping of the branched chain α-ketoacid dehydrogenase dihydrolipoyl transacylase (BCKD-E2) protein that reacts with sera from patients with idiopathic dilated cardiomyopathy. J Immunol 1994; 153:4754-4765.
65. Pohlner K, Portig I, Pankuweit S, et al. Identification of mitochondrial antigens recognized by antibodies in sera of patients with idiopathic dilated cardiomyopathy by two-dimensional gel electrophoresis and protein sequencing. Am J Cardiol 1997; 80:1040-1045.
66. Schultheiss HP, Ulrich G, Janda I, et al. Antibody mediated enhancement of calcium permeability in cardiac myocytes. J Exp Med 1988; 168:2105-2119.
67. Wallukat G, Morwinski M, Kowal K, et al. Antibodies against the β-adrenergic receptor in human myocarditis and dilated cardiomyopathy: β-adrenergic agonism without desensitization. Eur Heart J 1991; 12 (Suppl D):178-181.
68. Limas CJ, Limas C. β-receptor antibodies and genetics in dilated cardiomyopathy. Eur Heart J 1991; 12 (Suppl D):175-177.
69. Magnusson Y, Wallukat G, Waagstein F, et al. Autoimmunity in idiopathic dilated cardiomyopathy: characterization of antibodies against the β1-adrenoceptor with positive chronotropic effect. Circulation 1994; 89:2760-2767.
70. Jahns R, Boivin V, Siegmund C, et al. Autoantibodies activating human β1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999; 99:649-654.
71. Jahns R, Boivin V, Krapf T, et al. Modulation of β1-adrenoceptor activity by domain-specific antibodies and heart-failure associated autoantibodies. J Am Coll Cardiol 2000; 36:1280-1287.
72. Fu LX, Magnusson Y, Bergh CH, et al. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1993; 91:1964-1968.
73. Marriott JB, Goldman JH, Keeling PJ, et al. Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives. Heart 1996; 75:287-290.
74. Kuan AP, Zuckier L, Liao L, et al. Immunoglobulin isotype determines pathogenicity in antibody-mediated myocarditis in naïve mice. Circ Res 2000; 86:281-285.
75. Neu N, Rose NR, Beisel KW, et al. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol 1987; 139:3630-3636.
76. Smith SC, Allen PM. Myosin-induced myocarditis is a T cell-mediated disease. J Immunol 1991; 147:2141-2147.
77. Elliott JF, Liu J, Yuan ZN, et al. Autoimmune cardiomyopathy and heart block develop spontaneously in HLA-DQ8 transgenic IAbeta knockout NOD mice. Proc Natl Acad Sci U S A 2003; 100:13447-13452.
78. Taylor JA, Havari E, McInerney MF, et al. A spontaneous model for autoimmune myocarditis using the human MHC HLA-DQ8. J Immunol 2004; 172:2651-2658.
79. Hayward SL, Lopez-Bautista N, Suzuki K, et al. CD4 T cells play major effector role and CD8 T cells initiating role in spontaneous autoimmune myocarditis of HLA-DQ8 transgenic Iab knockout nonobese diabetic mice. J Immunol 2006; 176:7715-7725.
80. Taneja V, Behrens M, Cooper LT, et al. Spontaneous myocarditis mimicking human disease occurs in the presence of an appropriate MHC and non-MHC background in transgenic mice. J Mol Cell Cardiol 2007; 42:1054-1064. This study confirms previous studies [77-79] and expands them, as in this transgenic murine model spontaneous autoimmune myocarditis to cardiac myosin occurs in the context of HLA-DQ8, an allele known to be associated with susceptibility to human autoimmune diseases like rheumatoid arthritis and T1D, in females, thus providing insight into the pathogenesis of heart disease in women.
81. Guler ML, Ligons DL, Wang Y, et al. Two autoimmune diabetes loci influencing T cell apoptosis control susceptibility to experimental autoimmune myocarditis. J Immunol 2005; 174:2167-2173.
82. - regulatory T cells. J Immunol 2006; 176:4748-4756.
83. Jane-wit D, Altuntas CZ, Johnson JM, et al. β1-Adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis. Circulation 2007; 116:399-410. This interesting experimental study shows that β1-adrenergic receptor autoantibody-mediated apoptosis may be one mechanism leading to autoimmune DCM.
84. Mao W, Fukuoka S, Iwai C, et al. Cardiomyocyte apoptosis in autoimmune cardiomyopathy: mediated via endoplasmic reticulum stress and exaggerated by norepinephrine. Am J Physiol Heart Circ Physiol 2007; 293:H1636-H1645. This experimental study reports that autoantibody-mediated cardiomyocyte apoptosis, a possible mechanism leading to autoimmune DCM, may result from endoplasmic reticulum stress and may be potentiated by norepinephrine.
85. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291:319-322.
86. Mrena S, Savola K, Kulmala P, et al. Genetic modification of risk assessment based on staging of preclinical type 1 diabetes in siblings of affected children. J Clin Endocrinol Metab 2003; 88:2682-2689.
87. Warraich RS, Griffiths E, Falconar A, et al. Human cardiac myosin autoantibodies impair myocyte contractility: a cause-and-effect relationship. FASEB J 2006; 20:651-660.
88. Mobini R, Staudt A, Felix SB, et al. Hemodynamic improvement and removal of autoantibodies against the β1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun 2003; 20:345-350.
89. Urayama O, Shutt H, Sweadner J. Identification of three isozyme proteins of the catalytic subunit of the Na,K-ATPase in rat brain. J Biol Chem 1989; 264:8271-8280.
90. Jahns R, Boivin V, Hein L, et al. Direct evidence for a β1-adrenergic receptor directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004; 113:1419-1429.
91. Nikolaev VO, Boivin V, Stork S, et al. A novel fluorescence method for the rapid detection of functional β1-adrenergic receptor autoantibodies in heart failure. J Am Coll Cardiol 2007; 50:423-431. Using FRET, sera classified as antibody-negative by previous methods were found to contain low-activator antibodies. In addition, it was reported that β-blockers were not able to prevent antibody-induced receptor activation, but this was accomplished by blocking peptides.
92. Jahns R, Boivin V, Lohse MJ, et al. β1-Adrenergic receptor function, autoimmunity and pathogenesis of dilated cardiomyopathy. Trends Cardiovasc Med 2006; 16:20-24.
93. Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003; 107:857-863.